To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on Wednesday, July 9, 2025 at 12:00 pm ET. The event, moderated by Michael Ropacki, PhD and Oryzon's CMO for CNS, will f ...

MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan- McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phe ...

Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will give an update on corporate progress at several international events in May-June. Oryzon will attend the Foro Medcap 2025, which will take place at the Madrid Stock Exchange palace in Ma ...

Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafidemstatOryzon will also explore the targeted activity of iadademstat in several difficult-to-treat neuroendocrine cancersFunding covers 64% of Oryzon’s VANDAM project total budgetFurther reinforces Oryzon’s robust financial standing M ...